Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT07122219
Recruiting Not applicable

Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons

NCT07122219 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2024-10-01
Last updated
2025-12-29

Condition(s) studied

HIVHepatitis C Virus (HCV)

Investigational drug(s) / intervention(s)

NIATx

NIATx: The Network for the Improvement of Addiction Treatment (NIATx) model uses a bundle of implementation tools that include expert facilitation (coaching) and quality process improvement specifically for behavioural healthcare settings to improve access and retention in treatment.

Study summary

This study is focused on improving the implementation of Prison Needle Exchange Programs (PNEPs) in Canadian federal prisons, with the goal of increasing the uptake of these programs among people who inject drugs in prison. The study is being conducted in nine federal prisons, including five women's prisons, where a higher proportion of incarcerated individuals report a history of injection drug use. This study aims to improve PNEP adoption and sustainability by identifying barriers and facilitators and implementing evidence-based strategies to enhance program engagement.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All people incarcerated at a study site during the intervention period Exclusion Criteria: \- None (site level intervention)

Primary outcome measure(s)

Trial sites (9)

FacilityCityRegionStatus
Edmonton Institution for Women Edmonton Alberta Not Yet Recruiting
Fraser Valley Institution for Women Abbotsford British Columbia British Columbia Not Yet Recruiting
Mission Institution Mission British Columbia Not Yet Recruiting
Dorchester Medium Dorchester New Brunswick Recruiting
Atlantic Institution Smiths Crossing New Brunswick Recruiting
Nova Institution for Women Truro Nova Scotia Recruiting
Joyceville Institution Kingston Ontario Not Yet Recruiting
Grand Valley Institution for Women Kitchener Ontario Not Yet Recruiting
Joliette Institution for Women Joliette Quebec Not Yet Recruiting

More McGill University Health Centre/Research Institute of the McGill University Health Centre trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07122219 on ClinicalTrials.gov ↗ ← All trials in Canada